

## Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 40<sup>th</sup> Annual J.P. Morgan Healthcare Conference.

Adaptive Biotechnologies' management is scheduled to present on Monday, January 10<sup>th</sup> at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. This presentation time has been updated from a previous announcement and reflects the current schedule. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: <u>www.adaptivebiotech.com</u>.

## **About Adaptive Biotechnologies**

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have three commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

## ADAPTIVE INVESTORS

Karina Calzadilla, Vice President, Investor Relations 201-396-1687 Carrie Mendivil, Gilmartin Group investors@adaptivebiotech.com

ADAPTIVE MEDIA Erica Schmitt 206-279-2423 media@adaptivebiotech.com